• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ethos Files Registration Statement for Proposed Initial Public Offering

By: Ethos Technologies Inc via GlobeNewswire
September 26, 2025 at 13:50 PM EDT
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

AUSTIN, Texas, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced that it filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its Class A common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined.

Ethos intends to list its Class A common stock on the Nasdaq Global Select Market under the ticker symbol “LIFE.”

Goldman Sachs & Co. LLC and J.P. Morgan are acting as lead book-running managers for the offering. BofA Securities, Barclays, Citigroup, and Deutsche Bank Securities are acting as additional book-running managers. Citizens Capital Markets, William Blair, and Baird are acting as co-managers.

The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus related to the proposed offering, when available, may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Ethos

Ethos is a leading life insurance technology company on a mission to protect families by democratizing access to life insurance and empowering agents at scale. With its robust three-sided technology platform, Ethos is transforming the life insurance experience for consumers, agents, and carriers alike. Ethos offers instant, accessible products and a seamless online process that requires no medical exams and just a few health questions; it eliminates traditional barriers, making it easier than ever for everyone to protect their families. Each month, Ethos issues billions in coverage, redefining how life insurance is bought, sold, and underwritten.

Contact

Media
Allyson Savage, VP Communications, Ethos
Press@ethos.com

Investors
Aaron Turner, VP Investor Relations, Ethos
IR@ethos.com


Primary Logo

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More
News headline image
ArriVent BioPharma’s ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study ↗
Today 0:02 EDT
Via MarketBeat
Topics Initial Public Offering
Tickers AVBP
News headline image
Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study ↗
October 26, 2026
Via MarketBeat
Tickers ORKA
News headline image
Incyte Highlights Promising Early Data for ’890 and ’734 in GI Cancers ↗
October 26, 2026
Via MarketBeat
Tickers INCY
News headline image
What Elevra Lithium (ELVR) Said on Its Q1 Earnings Call ↗
October 26, 2026
Via MarketBeat
Topics Earnings Stocks
Tickers ELVR
News headline image
AstraZeneca Highlights Breakthrough Cancer Data at ESMO 2026 Investor Update ↗
October 26, 2026
Via MarketBeat
Topics ETFs
Tickers ARM AZN

Recent Quotes

View More
Symbol Price Change (%)
AMZN  249.09
+0.00 (0.00%)
AAPL  343.91
+0.00 (0.00%)
AMD  531.28
+0.00 (0.00%)
BAC  50.52
+0.00 (0.00%)
GOOG  314.19
+0.00 (0.00%)
META  630.56
+0.00 (0.00%)
MSFT  532.60
+0.00 (0.00%)
NVDA  216.00
+0.00 (0.00%)
ORCL  126.06
+0.00 (0.00%)
TSLA  391.62
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap